The cancer drug developer's $12.8m seed round included Eli Lilly, and Lilly New Ventures' Brad Robling is a board observer.

US-based cancer treatment developer Auron Therapeutics closed a $12.8m seed round yesterday that included pharmaceutical firm Eli Lilly.

Polaris Partners, Arkin Bio Ventures and Qiming Venture Partners USA co-led the round, which also featured American Cancer Society’s investment arm BrightEdge, as well as Casdin Capital and private investor Franklin Berger.

Auron is developing cancer therapies intended to restore malignant cells to a normal state rather than trying to kill them. The funding will help it advance its lead programme towards…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn